NKTR-118 + NKTR-118 + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Opioid-Induced Constipation (OIC)

Conditions

Opioid-Induced Constipation (OIC)

Trial Timeline

Mar 1, 2011 → Aug 1, 2012

NCT ID

NCT01309841

About NKTR-118 + NKTR-118 + Placebo

NKTR-118 + NKTR-118 + Placebo is a phase 3 stage product being developed by AstraZeneca for Opioid-Induced Constipation (OIC). The current trial status is completed. This product is registered under clinical trial identifier NCT01309841. Target conditions include Opioid-Induced Constipation (OIC).

What happened to similar drugs?

4 of 20 similar drugs in Opioid-Induced Constipation (OIC) were approved

Approved (4) Terminated (8) Active (9)

✅Naldemedine + PlaceboShionogiApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

✅Methylnaltrexone + PlaceboBausch HealthApproved

🔄Naldemedine + PlaceboShionogiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01395524	Phase 3	Completed	Jul 1, 2011	Sep 1, 2012	Opioid-Induced Constipation (OIC)
NCT01384292	Phase 3	Terminated	Jun 1, 2011	Sep 1, 2012	Opioid-Induced Constipation
NCT01309841	Phase 3	Completed	Mar 1, 2011	Aug 1, 2012	Opioid-Induced Constipation (OIC)
NCT01323790	Phase 3	Completed	Mar 1, 2011	Sep 1, 2012	Opioid-Induced Constipation (OIC)

Competing Products

20 competing products in Opioid-Induced Constipation (OIC)

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naloxegol	Kyowa Kirin	Pre-clinical	26
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
Naloxegol + Placebo Oral Capsule	AstraZeneca	Phase 2	27
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	40
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
CB-5945 + Placebo	Merck	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Tegaserod	Novartis	Phase 3	32
Methylnaltrexone bromide + Placebo	Pfizer	Phase 2	35
ALKS 37 + Placebo	Alkermes	Phase 2	32